People channel feed – Endpoints News

People channel feed

After a bruising turn as Sarepta CEO, Chris Garabedian is back in biotech with a new role as godfather to a bunch of startups

9 years ago

AstraZeneca throws a monkey wrench in new GSK CEO’s first hiring decision, suing Luke Miels

9 years ago

With major backing from New York and China, Athenex sets sights on a $100M cancer drug IPO

9 years ago

Biogen CSO Artavanis-Tsakonas heads back to Harvard, lab funding in hand

9 years ago

Genzyme founder, biotech entrepreneur and industry legend Henri Termeer dies

9 years ago

Glaxit: Flagging a looming threat from Gilead and a weak pipeline, Neil Woodford is giving up on GSK and pulling out

9 years ago

From Biogen’s buy side to biotech CEO: Josh Mandel-Brehm joins the Polaris family as a serial entrepreneur in the making

9 years ago

Jeremy Levin joins the biotech IPO rush, gaining $75M for Ovid’s R&D game plan

9 years ago

Serial startup scientist Ronald Evans tests a new Mighty Mouse drug, making marathon runners with a pill

9 years ago

GenSight vet Combal grabs $40M from Novartis, Roche group for second-wave gene therapy biotech

9 years ago

Genentech cancer R&D vet Raphaël Rousseau jumps ship, joins Gritstone

9 years ago

Tom Lynch outlines his comeback strategy for Bristol-Myers’ badly bruised R&D organization

9 years ago

Ed Kaye preps a surprising exit from Sarepta, spurring chatter about a possible sale

9 years ago

Scangos left Biogen in style, taking a final $17.7M compensation package for one last, disappointing year

9 years ago

Regeneron’s CEO, CSO saw their compensation slashed in ’16 — but it’s still a jaw-dropping sum

9 years ago

Dear Alexion: Geoff Meacham has some tough love to offer as you plan the rest of your year

9 years ago

Scoop: Turing CEO and Shkreli ally Ron Tilles is out as CEO, R&D chief Salinas takes the helm and board vote looms

9 years ago

With his day(s) in court looming, Martin Shkreli and his former lawyer win separate fraud trials

9 years ago

Ex-Dendreon chief Mitch Gold steers his way back to the public markets, looking to jumpstart a new clinical program

9 years ago

Incyte doubles down on CEO Hervé Hoppenot’s pay package — big but not stupid

9 years ago

Chalk up one more biotech startup for MIT’s Bob Langer

9 years ago

Confident he’ll be exonerated on fraud charges, Martin Shkreli is working on another attempt to “shock and awe”

9 years ago

Jeremy Levin spotlights a trendy new way to build a pipeline with his $86M IPO for Ovid

9 years ago

David Meeker starts the next chapter of his long biotech career as chairman of the board

9 years ago

First page Previous page 95 96 979899 100 101 Next page Last page